ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy

被引：0

作者：

Evans, T. R. Jeffry

Kudo, Masatoshi

Cheng, Ann-Lii

Wyrwicz, Lucjan S.

Ngan, Roger Kc

Blanc, Jean-Frederic

Baron, Ari David

Vogel, Arndt

Ikeda, Masafumi

Piscaglia, Fabio

Qin, Shukui

Hoshi, Taisuke

Tamaki, Ryuji

Funahashi, Yasuhiro

Okpara, Chinyere E.

Sagane, Koji

Xing, Dongyuan

Minoshima, Yukinori

Finn, Richard S.

机构：

[1] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[2] Kindai Univ, Fac Med, Osaka, Japan

[3] Natl Taiwan Univ Hosp, Taipei, Taiwan

[4] Natl Taiwan Univ Canc Ctr, Taipei, Taiwan

[5] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland

[6] Univ Hong Kong, Hong Kong, Peoples R China

[7] Univ Bordeaux, Bordeaux, France

[8] Sutter Calif Pacif Med Ctr, San Francisco, CA USA

[9] Hannover Med Sch, Hannover, Germany

[10] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[11] Univ Bologna, IRCCS Azienda Osped, Bologna, Italy

[12] Nanjing Bayi Hosp, Nanjing, Jiangsu, Peoples R China

[13] Eisai & Co Ltd, Ibaraki, Japan

[14] Eisai Ltd, Hatfield, Herts, England

[15] Eisai Inc, Nutley, NJ USA

[16] UCLA Med Ctr, Geffen Sch Med, Los Angeles, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4094

引用

页数：1

共 50 条

[1] Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT
Baron, Ari David
Lopez, Carlos Lopez
Chang, Stephen Lam
Piscaglia, Fabio
Ramji, Zahra
Ren, Min
Estenson, Kasey
Vogel, Arndt
Gholam, Pierre
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)
Cheng, A. -L.
Finn, R. S.
Qin, S.
Han, K. -H.
Ikeda, K.
Piscaglia, F.
Baron, A.
Park, J. -W.
Han, G.
Jassem, J.
Blanc, J. F.
Vogel, A.
Komov, D.
Evans, T. J.
Lopez, C.
Dutcus, C.
Ren, M.
Kraljevic, S.
Tamai, T.
Kudo, M.
ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 211 - 211
[3] Phase III Trial of Lenvatinib (LEN) vs Sorafenib (SOR) in First-Line Treatment of Patients (PTS) with Unresectable Hepatocellular Carcinoma (uHCC)
Cheng, Ann-Lii
Finn, Richard S.
Qin, Shukui
Han, Kwan-Hyub
Ikeda, Kenji
Piscaglia, Fabio
Baron, Ari
Park, Joong-Won
Han, Guohong
Jassem, Jacek
Blanc, Jean Frederic
Vogel, Arndt
Komov, Dmitry
Evans, T. R. Jeffry
Lopez, Carlos
Dutcus, Corina
MinRen
Kraljevic, Silvija
Tamai, Toshiyuki
Bower, John
Kudo, Masatoshi
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 116 - 116
[4] Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).
Cheng, Ann-Lii
Finn, Richard S.
Qin, Shukui
Han, Kwang-Hyub
Ikeda, Kenji
Piscaglia, Fabio
Baron, Ari David
Park, Joong-Won
Han, Guohong
Jassem, Jacek
Blanc, Jean -Frederic
Vogel, Arndt
Komov, Dmitry
Evans, T. R. Jeffry
-Lopez, Carlos Lopez
Dutcus, Corina E.
Ren, Min
Kraljevic, Silvija
Tamai, Toshiyuki
Kudo, Masatoshi
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[5] Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]
Finn, R. S.
Kudo, M.
Cheng, A-L.
Wyrwicz, L.
Ngan, R.
Blanc, J. F.
Baron, A. D.
Vogel, A.
Ikeda, M.
Piscaglia, F.
Han, K-H.
Qin, S.
Minoshima, Y.
Kanekiyo, M.
Ren, M.
Dairiki, R.
Tamai, T.
Dutcus, C. E.
Funahashi, Y.
Evans, T. R. J.
ANNALS OF ONCOLOGY, 2018, 29
[6] Characterization of tumor response with lenvatinib (LEN) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in REFLECT
Mahipal, A.
Cheng, A-L.
Kudo, M.
Burgoyne, A.
Kalyan, A.
Lencioni, R.
Lopez, C.
Pracht, M.
Daniele, B.
Palmer, D.
Baron, A.
Park, J-W.
Estenson, K.
Christou, V.
Ren, M.
Vogel, A.
ANNALS OF ONCOLOGY, 2024, 35 : S76 - S77
[7] Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)
Finn, R. S.
Kudo, M.
Cheng, A-L.
Wyrwicz, L.
Ngan, R.
Blanc, J-F.
Baron, A. D.
Vogel, A.
Ikeda, M.
Piscaglia, F.
Han, K-H.
Qin, S.
Minoshima, Y.
Funahashi, Y.
Ren, M.
Dairiki, R.
Sachdev, P.
Tamai, T.
Dutcus, C.
Evans, T. R. J.
ANNALS OF ONCOLOGY, 2017, 28
[8] Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses.
Kudo, Masatoshi
Yau, Thomas
Decaens, Thomas
Sangro, Bruno
Qin, Shukui
Da Fonseca, Leonardo
Karachiwala, Hatim
Park, Joong-Won
Gane, Edward
Pinter, Matthias
Tai, David
Santoro, Armando
Pizarro, Gonzalo
Chiu, Chang-Fang
Schenker, Michael
He, Aiwu Ruth
Hu, Nan
Jimenez Exposito, Maria Jesus
Stromko, Caitlyn
Galle, Peter Robert
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 520 - 520
[9] Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).
Lencioni, Riccardo
Kudo, Masatoshi
Finn, Richard S.
Qin, Shukui
Han, Kwang-Hyub
Ikeda, Kenji
Cheng, Ann-Lii
Piscaglia, Fabio
Han, Guohong
Ikeda, Masafumi
Simon, Krzysztof
Komov, Dmitry
OuYang, Xuenong
Evans, T. R. Jeffry
Sung, Max W.
Binder, Terri A.
Damon, Andrew
Kraljevic, Silvija
Ren, Min
Ryoo, Baek-Yeol
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[10] Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW Asian subgroup analysis
Yau, T.
Galle, P. R.
Decaens, T.
Sangro, B.
Qin, S.
Park, J-W.
Ikeda, M.
Tai, D. W. M.
Chiu, C-F.
Chon, H. J.
Kang, Y-K.
Hiraoka, A.
Huang, Y-H.
Lee, T-Y.
Numata, K.
Yamashita, T.
Ogata, T.
Hreiki, J.
Lu, Y.
Kudo, M.
ANNALS OF ONCOLOGY, 2024, 35 : S1450 - S1451

← 1 2 3 4 5 →